Resilience, Risk, and Reinvention

What's Needed for Life Science's Next Chapter in Growth

2/11/2026
Our life sciences specialists are available to discuss your needs. 

From IPO scrutiny to supply chain risk and AI-driven innovation, life sciences leaders face a pivotal moment for growth and resilience.

Trade uncertainty, pricing pressure, evolving regulatory expectations, and cautious capital markets are reshaping how biotech and pharmaceutical organizations pursue growth. At the same time, rapid advances in artificial intelligence, manufacturing analytics, and clinical innovation are creating new opportunities for companies that can execute with discipline and foresight.

This Industry Pulse brings together perspectives from Crowe, Forbes, and Investment News Network to examine what it will take for life sciences organizations to succeed in this next chapter. The insights explore market volatility, IPO readiness, investor scrutiny, and the long-term implications of supply chain resilience and national competitiveness.

Inside this Industry Pulse, you’ll explore:

  • The latest biotech and pharma market dynamics, including tariff impacts, M&A trends, and investor sentiment
  • How life sciences companies can drive value and reduce risk throughout the IPO process
  • Why resilience, operational rigor, and long-term strategy are critical to sustaining innovation and growth

Together, these articles highlight why life sciences leaders must balance scientific advancement with financial discipline, regulatory readiness, and strategic reinvention.

Complete the form below to access these insights

Captcha is required.

Related insights

loading gif
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.
Two business professionals reviewing information on a laptop and tablet during a collaborative discussion.
When Life Sciences Companies Need Compliance Expertise
Explore when life sciences companies need compliance expertise to manage regulatory risk, support growth, and build the right capabilities.
Professionals engaged in a presentation during a business meeting.
Top Risks in Internal Audit for 2027
In this webinar recording, Crowe specialists explore risks for internal audit in 2027 and share ideas to strengthen governance and compliance.
Life sciences researchers conduct laboratory testing, highlighting operational risks relevant to internal audit planning.
Top Risk Areas for Internal Audit Planning: Life Sciences
Crowe specialists review 2027 internal audit planning for life sciences organizations, including for cybersecurity, data privacy, AI, and compliance.